BioMarketGroup.com presents: Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
Report Published: 2010-06-24
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Alternative binding peptide molecules, derived from combinatorial scaffold libraries, are now challenging traditional antibodies.
This report comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. The report extensively analyses 125 identified targets of peptide drugs, organized into 103 drug target strategies, and assesses them in 52 different cancer indications.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty.
The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in breast cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization.
Digg.com
Stumbleupon.com
Del.icio.us
Facebook
Reddit.com